Tianjin Chase Sun Pharmaceutical Co., Ltd. (hereafter referred to as Chase Sun), founded in 1996, was among the first enterprises listed on the Growth Enterprise Market in 2009 (stock code: 300026). Chase Sun is a state-owned holding company subordinate to the State-owned Assets Supervision and Administration Commission. Chengdu Better City Investment Group, the controlling shareholder of Chase Sun, is a Fortune Global 500 company that holds the 466th rank.
Chase Sun runs the business in six major fields: Chinese medicine granules, finished pharmaceutical products, raw materials and excipients, medical devices, healthcare services, and smart supply chain for pharmaceutical and medical devices. Chase Sun owns two country-level research and development platforms, namely, National Enterprise Technology Center, and National-Local Joint Engineering Research Center for Key Technologies of Traditional Chinese Medicine Granules. Chase Sun has also received many honors, including National High-Tech Enterprise, National Technology Innovation Demonstration Enterprise, National Poverty Alleviation Advanced Group, and National Workers Vanguard. Chase Sun ranks 41st in the Top 100 List of China's Pharmaceutical Enterprises and 14th in the Top 100 List of Chinese Patent Medicine Enterprises. In 2022, Chase Sun's income from the main business was RMB 6.65 billion, with a total profit of RMB 716 million and total assets of RMB 12.631 billion.
The Chinese medicine granules business centers around the Kangrentang Full Ingredients ® Chinese medicine granules product line. So far, Chase Sun has built 8 smart manufacturing bases in Beijing, Tianjin, Hebei, Henan, Hubei, Gansu, Chongqing, and Shandong. Chase Sun enforces strict protocols for the cultivation of medicinal herbs and the preparation of Chinese herbal medicine according to ancient methods. A whole-process quality traceability system has been established to tighten quality control. Chase Sun has the leading market share in the industry.
The finished pharmaceutical products business consists of 11 categories, 26 product varieties, and 39 product specifications. Xuebijing Injection is Chase Sun's core product with proprietary intellectual property right. Post-marketing evidence-based research on Xuebijing Injection for more than 10 years has demonstrated that the medicine can reduce the mortality of severe pneumonia by 8.8%. A related paper on Xuebijing Injection has been published in the international leading journal Critical Care Medicine. The effectiveness of the Xuebijing Injection has already been recognized by international authoritative experts. During the COVID-19 epidemic, Xuebijing Injection is one of the "three medicines and three formulas" of traditional Chinese medicines recommended by Chinese healthcare authorities due to its proven clinical efficacy. Xuebijing Injection has also been included in several editions of Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia. Xuebijing Injection is a traditional Chinese medicine against COVID-19 that has been strongly recommended to the world.
Chase Sun has three subsidiaries in the raw materials and excipients business, namely, Zhanwang Pharmaceutical, Enoray Biopharmaceutical, and Wantai BioPharm. All of them are leading enterprises in the sub-fields, selling products to over 50 countries and districts throughout the world. ChoiceMMed and Wenhe Medical Equipment are two subsidiaries running the medical device businesses. ChoiceMMed fingertip pulse oximeter is among the first batch of supply-guaranteed products during China's fight against the COVID-19 epidemic. Chase Sun's healthcare service business has been thriving over the years due to an abundance of traditional Chinese medicine experts collaborating with Chase Sun. The Shangyi Mingjia Traditional Chinese Medicine Clinic has been opened in over 20 cities offline. Chase Sun has also founded an online traditional Chinese medicine Internet Hospital, where more than 50 thousand traditional Chinese medicine doctors have been registered. The smart supply chain for pharmaceutical and medical devices is dedicated to providing whole-process digital management services for medical institutions, which range from procurement, logistics, and usage to maintenance.
Chase Sun's vision is to inherit and develop traditional Chinese medicine and address human health challenges. We are committed to accelerating the integration of digital applications in the six major business areas. By innovating the whole industrial chain, we have been continuously practicing our two main value propositions: to provide people with access to high-quality traditional Chinese medicine services and to advance China's healthcare quality. We have been striving to become the leader of Chinese medicine.
Development journey
